La caverna de Josep Palau i Fabre (1952-1969): teatre versus al·legoria filosòfica per a representar i impedir el final tràgic i fosc del lluminós art de pensar.

What is the use of performing the myth of the cave from book VII of the Republic by Plato? Josep Palau i Fabre, considers that, in Plato's dialogues, the speakers are mere instruments at the service of his dialectical goal. The aim of this article is to show how, by turning the myth into a tragedy and also by relying on Heraclitus's conflict or war of opposites, the playwright succeeds in favoring a sort of thought which is not one-sided or univocal. On the contrary, in Palau i Fabre's La Caverna, the tragic hero, that is, the released prisoner transformed by the light of Reality and finally killed by his "cavemates" -after having been imprisoned again and having tried to rescue them from their ignorance or shadows-, still leaves to them his powerful experience of the agonistikos thought, which might bear fruit in their life to come.

[Illustrations de Art de chevalerie] / [Non identifié] ; Johann Hacobi von Wallhausen, aut. du texte

Comprend : [Frontispice : éléments d'architecture, figures de deux soldats en armure, scène de charge de cavalerie.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.68 (ou 446) : art équestre. Manière de monter à cheval.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.72 (ou 452) : art équestre. Manière de faire tourner le cheval en une ronde ou dans une figure serpentine.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.78 (ou 460) : art équestre. Manière de faire monter une côte à un cheval, de lui faire sauter un obstacle.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.80 (ou 464) : art équestre. Manière de faire traverser un fleuve à un cheval, de lui faire traverser un pont étroit et de lui faire dominer sa peur du feu. ] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.84 (ou 470) : art équestre. Manière de combattre avec un lance sur un cheval.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.86 (ou 474) : art équestre. Manière de combattre avec un lance ou avec une épéesur un cheval.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.88 (ou 478) : art équestre. Manière de combattre avec des arquebuses sur un cheval.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.90 (ou 482) : art équestre. Manière de combattre avec des arquebuses ou des épées sur un cheval.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.94 (ou 488) : art équestre. Manière de combattre entre un fantassin et un cavalier.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.96 (ou 492) : art équestre. Manière de combattre entre un fantassin et un cavalier ou entre deux cavalier armés d'épées.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.100 (ou 498) : art équestre. Manière de combattre entre cavaliers.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.102 (ou 502) : art équestre. Manière de combattre entre deux adversaires à pied.] [Cote : Res Z Fontanieu 103 (5)] ; [Pl. dépl. en reg. p.106 (ou 508) : art équestre. Scène de batailel avec charge de cavalerie.] [Cote : Res Z Fontanieu 103 (5)] ; [Vigentte p.512 : marque d'imprimeur.] [Cote : Res Z Fontanieu 103 (5)]

[Illustrations de L'art du fabricant de velours de coton] / Bernard, grav.; Fossier, dess. ; Jean-Marie Roland de la Platière, aut. du texte

Comprend : [Bandeau folio Aij : allégorie de la Justice. Homme écrivant, singe. Ornements à la Bérin.] [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.1 : de la mécanique à carder le coton. Vues et développements de la machine à carder le coton.] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.2 : de la mécanique à carder le coton. Machine à carder le coton.] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.3 : de la mécanique à carder le coton. Machine à carder le coton. Fig.4 : petits cadres en fer, implantés sur la charpente de la mécanique, sur lesquels s'appuie et tourne l'axe des cylindres.] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.4 : de la mécanique à filer le coton et de la manière de s'en servir.] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.5 : de la mécanique à filer le coton et de la manière de s'en servir.] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.6 : fabrication du velours. Fig.1 : moulins à retordre les fils de coton, doublés pour la châine des velours] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.7 : fabrication du velours. Fig.1 : vue perspective du métier monté et en travail.] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.8 : fabrication du velours. Armure de piqué pour un carreau quatre points simple ou double, velours velvet-ret, croisé, piqué ou cannelé. Fig.8 : fabrication d'une toile sans lisière.] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.9 : fabrication du velours. Le fourneau à brûler, griller ou raser les velours de coton et de la manière de faire cette opération.] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.10 avec 3 vignettes : vignette 1, fabrication du velours. Des couleurs en bon teint. Atelier de teinture pour les coulers ordinaires, les garançages etc. Vignette 2 : atelier de teinture pour les cuves de bleu. Vignette 3 : atelier de teinture pour les tones de noir.] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257] ; [Pl.11 : fabrication du velours. Des couleurs en bon teint. De la cuve du bleu à chaud. Mécanique à imprimer au cylindre les toiles, croisés, satinettes, velours de coton etc. Mécanique à découper les velours cannelés et le velvet-ret avec l'ouvrier vu en travail. ] L'art du fabricant de velours de coton. [Cote : Res Atlas V 117/Microfilm R 101257]

A Phase IIB, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in HIV-1-infected Patients

Background: Vacc-4x is a peptide-based HIV therapeutic vaccine to conserved domains on p24Gag. Recently conserved 'sectors' on HIV p24, critical for virus viability and thereby immunologically vulnerable have been identified. Elite controllers target immune responses to such regions. The Vacc-4x peptides lie within a number of these conserved sectors of HIV p24. The co-primary endpoints of this study were to compare changes in CD4 counts and return to ART between treatmentand placebo groups during a 24 week treatment interruption. Secondary endpoints included safety, viral load and immunogenicity.Methods: This prospective, randomized, double blind phase IIB clinical study (NCT00659789) was carried out in 13 European and 5 US centers recruiting 135 patients on ART. After 6 immunizations on ART over 28 weeks, treatment was interrupted for up to 24 weeks (to week 52) (Vacc-4x n = 88; placebo n = 38). Immunological analyses (ELISPOT, proliferation, intracellular cytokine staining) were carried out at central laboratories.Results: There were no Vacc-4x-related serious adverse events. Of the 135 patients recruited (male n = 92; female n = 43), 126 patients completed the study. Median prestudy CD4 count was 712 (Vacc-4x) and 619 cells/mm3 (placebo), and median CD4 nadir 300 (Vacc-4x) and 285 cells/mm3 (placebo). There was no statistically significant difference between the two groups regarding change in CD4 counts (p = 0.12) or ART resumption (p = 0.89) during treatment interruption. A statistically significant treatment difference between Vacc-4x and placebo groupsfor viral load (VL) was found for patients who achieved a 6 month ART-free period (p = 0.0022). There was a positive correlation between ELISPOT responses and lower viral load in the Vacc-4x group compared to placebo (p = 0.02). Long-term follow-up of patients up t o week 104 was completed in June 2011.Conclusion: Vacc-4x was found to be safe and well tolerated. TheVacc-4x group experienced a significant reduction in viral load compared to placebo.

Effect of a governmentally-led physical activity program on motor skills in young children attending child care centers: a cluster randomized controlled trial.

OBJECTIVE: To assess the effect of a governmentally-led center based child care physical activity program (Youp'la Bouge) on child motor skills.Patients and methods: We conducted a single blinded cluster randomized controlled trial in 58 Swiss child care centers. Centers were randomly selected and 1:1 assigned to a control or intervention group. The intervention lasted from September 2009 to June 2010 and included training of the educators, adaptation of the child care built environment, parental involvement and daily physical activity. Motor skill was the primary outcome and body mass index (BMI), physical activity and quality of life secondary outcomes. The intervention implementation was also assessed. RESULTS: At baseline, 648 children present on the motor test day were included (age 3.3 +/- 0.6, BMI 16.3 +/- 1.3 kg/m2, 13.2% overweight, 49% girls) and 313 received the intervention. Relative to children in the control group (n = 201), children in the intervention group (n = 187) showed no significant increase in motor skills (delta of mean change (95% confidence interval: -0.2 (-0.8 to 0.3), p = 0.43) or in any of the secondary outcomes. Not all child care centers implemented all the intervention components. Within the intervention group, several predictors were positively associated with trial outcomes: 1) free-access to a movement space and parental information session for motor skills 2) highly motivated and trained educators for BMI 3) free-access to a movement space and purchase of mobile equipment for physical activity (all p < 0.05). CONCLUSION: This "real-life" physical activity program in child care centers confirms the complexity of implementing an intervention outside a study setting and identified potentially relevant predictors that could improve future programs.Trial registration: Trial registration number: clinical trials.gov NCT00967460 http://clinicaltrials.gov/ct2/show/NCT00967460.

Qualitative analysis of barriers and facilitators encountered by HIV patients in an ART adherence programme.

Background Medication adherence is a complex, dynamic and changing behaviour that is affected by a variety of factors, including the patient's beliefs and life circumstances. Studies have highlighted barriers to medication adherence (e.g., unmanaged side effects or a lack of social support), as well as facilitators of medication adherence (e.g., technical simplicity of treatment and psychological acceptance of the disease). Since August 2004, in Lausanne (Switzerland), physicians have referred patients who are either experiencing or are at risk of experiencing problems with their HIV antiretroviral treatment (ART) to a routine interdisciplinary ART adherence programme. This programme consists of multifactorial intervention including electronic drug monitoring (MEMS(TM)). Objective This study's objective was to identify the barriers and facilitators encountered by HIV patients with suboptimal medication adherence (≤90 % adherence over the study period). Setting The community pharmacy of the Department of Ambulatory Care and Community Medicine in Lausanne (Switzerland). Method The study consisted of a retrospective, qualitative, thematic content analysis of pharmacists' notes that were taken during semi-structured interviews with patients and conducted as part of the ART adherence programme between August 2004 and May 2008. Main outcome measure Barriers and facilitators encountered by HIV patients. Results Barriers to and facilitators of adherence were identified for the 17 included patients. These factors fell into three main categories: (1) cognitive, emotional and motivational; (2) environmental, organisational and social; and (3) treatment and disease. Conclusion The pharmacists' notes revealed that diverse barriers and facilitators were discussed during medication adherence interviews. Indeed, the results showed that the 17 non-adherent patients encountered barriers and benefited from facilitators. Therefore, pharmacists should inquire about all factors, regardless of whether they have a negative or a positive impact on medication adherence, and should consider all dimensions of patient adherence. The simultaneous strengthening of facilitators and better management of barriers may allow healthcare providers to tailor care to a patient's specific needs and support each individual patient in improving his medication-related behaviour.

Samoyedic studies : a state-of-the-art report

Abstract